Research and Markets (http://www.researchandmarkets.com/research/nclmw3/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Paroxysmal Nocturnal Hemoglobinuria Overview
  3. Therapeutics Development
  4. Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview
  5. Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis
  6. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies
  7. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes
  8. Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies
  13. Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes
  14. Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
  • Achillion Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amyndas Pharmaceuticals LLC
  • Apellis Pharmaceuticals, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Novartis AG
  • Omeros Corporation
  • Ra Pharmaceuticals, Inc.
  • Regenesance BV
  • The International Biotechnology Center (IBC) Generium

For more information visit http://www.researchandmarkets.com/research/nclmw3/paroxysmal